Sign In
Buy SGEN
$228.74
+0 (+0%)
At Close: Mar 12, 2024
Federal Circuit Court of Appeals Vacates Infringement Judgment and Damages Award in Dispute between Daiichi Sankyo and Seagen
07:00am, Wednesday, 03'rd Dec 2025
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--On December 2, the U.S. Court of Appeals for the Federal Circuit (the Federal Circuit) reversed a decision from the U.S. District Court for the Eastern Di
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
08:31am, Friday, 01'st Aug 2025
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo
President Trump demands drugmakers slash prices within 60 days
06:54am, Friday, 01'st Aug 2025
CNBC's Joe Kernen reports on the latest news.
Refractory Metastatic Melanoma Pipeline Report 2025, with Focus on BioNTech SE, Y-mAbs and Therapeutics Seagen
01:36pm, Thursday, 20'th Mar 2025
Dublin, March 20, 2025 (GLOBE NEWSWIRE) -- The "Refractory Metastatic Melanoma - Pipeline Insight, 2025" clinical trials has been added to ResearchAndMarkets.com's offering. The report provides compre
Two Brothers, a Big Biotech Bet and an $8 Billion Payout
10:00am, Saturday, 13'th Apr 2024
Investors in a hedge fund from Baker Bros. Advisors recently received one of the largest windfalls ever following Pfizer's purchase of Seagen.
Pfizer: Seagen Acquisition Starting To Bear Fruit
01:05pm, Tuesday, 12'th Mar 2024
Pfizer's share price has stabilized since the company provided 2024 revenue and EPS guidance in late 2023. The success of Adcetris in a trial for relapsed/refractory DLBCL is a positive step for Pfize
Pfizer to close Seagen manufacturing plant in Seattle area following $43B acquisition
11:19am, Saturday, 02'nd Mar 2024
Pharma giant Pfizer, fresh off its $43 billion acquisition of Seagen, said it will shut down construction on a new 270,000 square-foot manufacturing facility Seagen was building north of Seattle near
Pfizer CEO doubles down on 2024 guidance, talks Seagen buy
05:03pm, Tuesday, 30'th Jan 2024
Pfizer (PFE) reported fourth-quarter earnings on Tuesday morning that beat. Wall Street expectations.
Cramer names biopharma companies to watch as industry mergers start to pile up
07:02pm, Friday, 05'th Jan 2024
CNBC's Jim Cramer pointed out the numerous mergers and acquisitions across the biopharma industry.
5 Biotech Acquisition Targets To Accumulate In 2024
01:05pm, Thursday, 21'st Dec 2023
Valuations in the biotech market have fallen, making it a good time for acquisitions in the industry. Investors should focus on commercial-stage biotech companies that generate revenue, as they provid
Pfizer Completes Acquisition of Seagen
07:39am, Thursday, 14'th Dec 2023
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Seagen Inc. (NASDAQ: SGEN), a global biotechnology company that discovers, develops a
Pfizer guides for US$61.5bn sales from Covid-19, Paxlovid, Seagen
10:23am, Wednesday, 13'th Dec 2023
Pfizer Inc (NYSE:PFE) said today that it is expecting $58.5 billion to $61.5 billion of sales in 2024 from Covid-19 vaccines, antiviral medicine Paxlovid and Seagen, with deal for the latter cancer dr
8 Tax-Loss Sell Alerts For December
11:07am, Tuesday, 12'th Dec 2023
Investors should consider tax-loss selling before December ends to offset capital gains. Two characteristics to consider for selling stocks are stocks bought at a higher price and broken companies wit
Pfizer to close Seagen acquisition after donating cancer drug rights
09:51am, Tuesday, 12'th Dec 2023
Pfizer Inc (NYSE:PFE) announced on Tuesday that it will donate the rights of royalties from sales of cancer drug Bavencio to the American Association for Cancer Research (AACR) in order to address con
Pfizer gets OK for $43-billion Seagen deal after donating cancer drug rights
07:06am, Tuesday, 12'th Dec 2023
Pfizer said on Tuesday it has agreed to donate the rights of royalties from sales of cancer drug Bavencio to address concerns from U.S. antitrust regulators related to its $43-billion deal to buy Seag
